{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pediatric+Patient+Safety&page=2",
    "query": {
      "condition": "Pediatric Patient Safety",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pediatric+Patient+Safety&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-06-26T10:29:43.026Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05267613",
      "title": "Endoscopic Evidence of Maintenance of Healing With Oral NEXIUM in Patients 1 to 11 Years Old With Erosive Esophagitis.",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Erosive Esophagitis"
      ],
      "interventions": [
        {
          "name": "Nexium 20mg",
          "type": "DRUG"
        },
        {
          "name": "Nexium 10mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "11 Years",
        "sex": "ALL",
        "summary": "1 Year to 11 Years"
      },
      "enrollment_count": 53,
      "start_date": "2022-07-01",
      "completion_date": "2026-08-19",
      "has_results": false,
      "last_update_posted_date": "2026-04-22",
      "last_synced_at": "2026-06-26T10:29:43.026Z",
      "location_count": 11,
      "location_summary": "Mobile, Alabama • Sacramento, California • Miami, Florida + 7 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05267613"
    },
    {
      "nct_id": "NCT00089583",
      "title": "48-Week Study Of GW433908 And Ritonavir Or GW433908 Alone, Twice Daily In Pediatric Patients With HIV Infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Infection, Human Immunodeficiency Virus I"
      ],
      "interventions": [
        {
          "name": "LEXIVA (GW433908)",
          "type": "DRUG"
        },
        {
          "name": "Ritonavir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "2 Years to 18 Years"
      },
      "enrollment_count": 110,
      "start_date": "2004-07",
      "completion_date": "2013-07",
      "has_results": true,
      "last_update_posted_date": "2017-03-07",
      "last_synced_at": "2026-06-26T10:29:43.026Z",
      "location_count": 16,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Oakland, California + 10 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00089583"
    },
    {
      "nct_id": "NCT01192568",
      "title": "Safety and Efficacy Evaluation of Oxybutynin Topical Gel In Children With Neurogenic Bladder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Overactive Detrusor",
        "Neurogenic Bladder"
      ],
      "interventions": [
        {
          "name": "Oxybutynin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "16 Years",
        "sex": "ALL",
        "summary": "3 Years to 16 Years"
      },
      "enrollment_count": 52,
      "start_date": "2011-05-17",
      "completion_date": "2023-10-24",
      "has_results": true,
      "last_update_posted_date": "2024-09-04",
      "last_synced_at": "2026-06-26T10:29:43.026Z",
      "location_count": 10,
      "location_summary": "Loma Linda, California • Orange, California • Aurora, Colorado + 7 more",
      "locations": [
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Jackson",
          "state": "Mississippi"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01192568"
    },
    {
      "nct_id": "NCT06173518",
      "title": "A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia",
        "Relapsed or Refractory B Cell Non-Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "AUTO1",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Autolus Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "0 Years to 18 Years"
      },
      "enrollment_count": 30,
      "start_date": "2023-11-16",
      "completion_date": "2027-11",
      "has_results": false,
      "last_update_posted_date": "2026-03-02",
      "last_synced_at": "2026-06-26T10:29:43.026Z",
      "location_count": 3,
      "location_summary": "Philadelphia, Pennsylvania • San Antonio, Texas • Salt Lake City, Utah",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06173518"
    },
    {
      "nct_id": "NCT02618434",
      "title": "Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 2)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Attention Deficit Hyperactivity Disorder (ADHD)"
      ],
      "interventions": [
        {
          "name": "SPN-810 (18 mg)",
          "type": "DRUG"
        },
        {
          "name": "SPN-810 (36 mg)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Supernus Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "12 Years",
        "sex": "ALL",
        "summary": "6 Years to 12 Years"
      },
      "enrollment_count": 297,
      "start_date": "2016-02-16",
      "completion_date": "2020-02-14",
      "has_results": true,
      "last_update_posted_date": "2024-03-18",
      "last_synced_at": "2026-06-26T10:29:43.026Z",
      "location_count": 32,
      "location_summary": "Chandler, Arizona • Little Rock, Arkansas • Imperial, California + 29 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Imperial",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Panorama City",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02618434"
    },
    {
      "nct_id": "NCT06983158",
      "title": "A Clinical Trial of CAP-002 Gene Therapy in Pediatric Patients With Syntaxin-Binding Protein 1 (STXBP1) Encephalopathy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Developmental and Epileptic Encephalopathy"
      ],
      "interventions": [
        {
          "name": "gene therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Capsida Biotherapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Months",
        "maximum_age": "7 Years",
        "sex": "ALL",
        "summary": "18 Months to 7 Years"
      },
      "enrollment_count": 1,
      "start_date": "2025-07-03",
      "completion_date": "2026-05-26",
      "has_results": false,
      "last_update_posted_date": "2026-06-10",
      "last_synced_at": "2026-06-26T10:29:43.026Z",
      "location_count": 4,
      "location_summary": "Aurora, Colorado • New York, New York • Philadelphia, Pennsylvania + 1 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06983158"
    },
    {
      "nct_id": "NCT05855083",
      "title": "Efficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk Hematopoietic Stem Cell Transplant TMA",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Thrombotic Microangiopathies",
        "Hematopoietic Stem Cell Transplantation"
      ],
      "interventions": [
        {
          "name": "Biological: narsoplimab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Omeros Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "28 Days",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "28 Days to 17 Years"
      },
      "enrollment_count": 18,
      "start_date": "2023-05-01",
      "completion_date": "2025-12",
      "has_results": false,
      "last_update_posted_date": "2025-03-25",
      "last_synced_at": "2026-06-26T10:29:43.026Z",
      "location_count": 8,
      "location_summary": "San Diego, California • Gainesville, Florida • Boston, Massachusetts + 5 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05855083"
    },
    {
      "nct_id": "NCT06274788",
      "title": "Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients With PNAC Who Require More Than Eight Weeks of Omegaven Treatment",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Parenteral Nutrition Associated Liver Disease (PNALD)",
        "Essential Fatty Acid Deficiency",
        "Malnutrition",
        "Pediatric ALL"
      ],
      "interventions": [
        {
          "name": "Omegaven® (fish oil triglycerides) Injectable Emulsion",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Fresenius Kabi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Day",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "1 Day to 17 Years"
      },
      "enrollment_count": 40,
      "start_date": "2024-12-15",
      "completion_date": "2027-03-01",
      "has_results": false,
      "last_update_posted_date": "2025-09-05",
      "last_synced_at": "2026-06-26T10:29:43.026Z",
      "location_count": 10,
      "location_summary": "Fountain Valley, California • Los Angeles, California • Chicago, Illinois + 7 more",
      "locations": [
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06274788"
    },
    {
      "nct_id": "NCT00761462",
      "title": "BAY 0 9867 Cipro Pediatric Use Study (QUIP)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Infectious Diseases"
      ],
      "interventions": [
        {
          "name": "Ciprofloxacin",
          "type": "DRUG"
        },
        {
          "name": "Non-quinolone antibiotic",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Months",
        "maximum_age": "16 Years",
        "sex": "ALL",
        "summary": "2 Months to 16 Years"
      },
      "enrollment_count": 1029,
      "start_date": "1999-10",
      "completion_date": "2008-01",
      "has_results": true,
      "last_update_posted_date": "2015-07-31",
      "last_synced_at": "2026-06-26T10:29:43.026Z",
      "location_count": 66,
      "location_summary": "Mobile, Alabama • Fort Smith, Arkansas • Corona, California + 58 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Fort Smith",
          "state": "Arkansas"
        },
        {
          "city": "Corona",
          "state": "California"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00761462"
    },
    {
      "nct_id": "NCT00819039",
      "title": "A Study of Aprepitant (MK-0869) in Pediatric Participants Undergoing Surgery (MK-0869-148)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Postoperative Nausea and Vomiting"
      ],
      "interventions": [
        {
          "name": "Aprepitant",
          "type": "DRUG"
        },
        {
          "name": "Ondansetron",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "6 Months to 17 Years"
      },
      "enrollment_count": 98,
      "start_date": "2009-01-26",
      "completion_date": "2013-03-12",
      "has_results": true,
      "last_update_posted_date": "2021-01-26",
      "last_synced_at": "2026-06-26T10:29:43.026Z",
      "location_count": 2,
      "location_summary": "Louisville, Kentucky • Nashville, Tennessee",
      "locations": [
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00819039"
    }
  ]
}